{
    "clinical_study": {
        "@rank": "70628", 
        "arm_group": [
            {
                "arm_group_label": "Infants, IBD mothers, anti TNF, pregnancy", 
                "description": "Infants born to mother with IBD receiving ant- TNF medications during pregnancy"
            }, 
            {
                "arm_group_label": "infants, IBD mothers, pregnancy, medications", 
                "description": "Infants born to mothers with IBD receiving non anti TNF medications during pregnancy"
            }
        ], 
        "biospec_descr": {
            "textblock": "Blood tests"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "1. To evaluate the immune response to vaccines in infants of IBD patients treated with\n           anti-TNF medications during pregnancy compared to infants of IBD mother not treated\n           with anti-TNF medications.\n\n        2. To evaluate the immune function of B and T cells at 3 months and one year of age in\n           infants of IBD patients treated with anti-TNF medications during pregnancy compared to\n           infants of non anti-TNF treated mothers.\n\n      The secondary aims are to follow anti TNF drug levels in infants born to IBD patients\n      treated with anti-TNF medications during pregnancy and to evaluate the risk of infections\n      during the first year of life in this population, compared to children of IBD patients not\n      treated with anti-TNF medications during pregnancy.\n\n      Significance -The results of this study have the potential to change clinical practice of\n      anti TNF treatment during pregnancy and the follow-up of infants born to these patients"
        }, 
        "brief_title": "Immune Function in Offsprings of Females With Inflammatory Bowel Disease (IBD) Treated With Anti-TNF Medications During Pregnancy", 
        "condition": "Inflammatory Bowel Disease", 
        "condition_browse": {
            "mesh_term": [
                "Inflammatory Bowel Diseases", 
                "Intestinal Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Children born to mothers with IBD who were treated with ant-TNF medications, other\n             medications or not medically treated for IBD during pregnancy .\n\n          2. Regular vaccination for hepatitis B at birth, 1 and 6 months of age and other\n             scheduled non-live vaccines at 2,4, and 6 months of age.\n\n          3. Inform consent signed by the parents.\n\n        Exclusion Criteria:\n\n          1. Children with intrauterine or perinatal infections, congenital diseases or\n             malformations.\n\n          2. Absence of immunization records.\n\n          3. Known immune deficiency of mother and/or child. 4. Mothers with hepatitis B"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "3 Months", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "This is a multicenter prospective controlled trial. The study population includes infants\n        born to mothers with IBD, divided into two groups: Study group- infants of IBD patients\n        treated with anti-TNF during pregnancy. Control group- infants of IBD patients treated\n        with non-anti TNF medications during pregnancy."
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02079441", 
            "org_study_id": "SHEBA-13-0613-BW-CTIL"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Anti- TNF", 
            "inflammatory bowel disease", 
            "pregnancy", 
            "infant", 
            "immunity", 
            "Immune function"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "number_of_groups": "2", 
        "official_title": "Immune Function in Offsprings of Females With Inflammatory Bowel Disease (IBD) Treated With Anti-TNF Medications During Pregnancy", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Antibodies to vaccine agents at age 12 months. 2. Immunoglobulin levels, B and T cell production (IgG subclasses, T cell subpopulation numbers) and function (response to mitogens and antigens) at age 3 months and 1 year", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02079441"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sheba Medical Center", 
            "investigator_full_name": "Batia Weiss", 
            "investigator_title": "Director, Pediatric Gastroenterology and Nutrition Unit", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Anti TNF drug level in cord blood", 
                "safety_issue": "No", 
                "time_frame": "birth"
            }, 
            {
                "measure": "Infection number and type during the first year of life", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Antibiotic use in the first year", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Breast feeding influence (with and without additional medications) on the immune function of the children", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Sheba Medical Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Schneider Children's Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Tel Aviv Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shaare Zedek Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Assaf-Harofeh Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Rambam Health Care Campus", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Sheba Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}